Fructose intake has increased substantially throughout the developed world and is associated with obesity, type 2 diabetes and non-alcoholic fatty liver disease. Currently, our understanding of the metabolic and mechanistic implications for immune cells, such as monocytes and macrophages, exposed to elevated levels of dietary fructose is limited. Here, we show that fructose reprograms cellular …
Month: Feb 2021
Clinical and Biological Correlates of White Matter Hyperintensities in Patients with #Behavioral-variant Frontotemporal #Dementia and #Alzheimer Disease
To test the hypothesis that white matter hyperintensities (WMH) in behavioral-variant frontotemporal dementia (bvFTD) and Alzheimer disease (AD) are associated with disease variables such as disease severity, cortical atrophy and cognition, we conducted a cross-sectional brain MRI study with volumetric and voxel-wise analyses. Methods: 129 patients (64 bvFTD, 65 AD) and 66 controls underwent high-resolution …
Risk‐adapted starting age of #breast cancer screening in women with a family history of #ovarian or other cancers: A nationwide cohort study
There is a lack of evidence‐based recommendations for the age at which women with a family history of cancers other than breast cancer should start breast cancer screening. METHODS Using Swedish family cancer data sets, the authors conducted a nationwide cohort study including 5,099,172 Swedish women born after 1931 (follow‐up, 1958‐2015). Accounting for calendar time, …
#Personality pathways to mortality: Interleukin-6 links conscientiousness to #mortality risk
Personality is associated consistently with mortality hazards, but the physiological pathways are not yet clear. Immune system dysregulation may be one such pathway due to its role in age-related morbidity and mortality. In this preregistered study, we tested whether interleukin-6 (IL-6) and C-reactive protein (CRP) mediated the associations between personality traits and mortality hazards. The …
#Statin treatment and #muscle symptoms: series of randomised, placebo controlled n-of-1 trials
To establish the effect of statins on muscle symptoms in people who had previously reported muscle symptoms when taking statins. Design Series of randomised, placebo controlled n-of-1 trials. Setting Primary care across 50 sites in the United Kingdom, December 2016 to April 2018. Participants 200 participants who had recently stopped or were considering stopping treatment …
2Medical.News 